Clinical trial
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
NCT00055237 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00055237 |
|---|---|
| Title | Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients |
| Official title | Phase II Study of Intravenous Recombinant Humanized Anti-Vascular Endothelial Cell Growth Factor Antibody (Bevacizumab) in Classical (HIV-Negative) and in AIDS-Associated Kaposi's Sarcoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kaposi's Sarcoma, HIV Infections, HIV Seronegativity |
| Intervention type | Biological |
| Interventions | Bevacizumab |
| Enrollment | 19 |
| Start date | Feb 26, 2003 |
| Primary completion | Mar 15, 2010 |
| Completion | Mar 15, 2010 |
| First posted | Feb 21, 2003 |
| Last update posted | Sep 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: